Medigene announces participation at upcoming investor and scientific conferences

Planegg - Medigene AG (FSE: MDG1, Prime Standard, TecDAX) today announced its participation at four upcoming investor and scientific conferences:

American Society of Hematology (ASH) Annual Meeting
Date: 9 - 12 December 2017
Location: Atlanta, USA

Guggenheim's 5th Annual Boston Healthcare Conference
Date: 13 December 2017
Location: Boston, USA

JP Morgan Healthcare Conference
Trout Access
Date: 8 - 11 January 2018
Location: San Francisco, USA

ODDO BHF Forum 2018
Date: 11 - 12 January 2018
Location: Lyon, France

Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard, TecDAX) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative immunotherapies to target various forms and stages of cancer. Medigene concentrates on the development of personalized T cell-based therapies, with associated projects currently in pre-clinical and clinical development.

For more information, please visit www.medigene.com

This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.

Contact Medigene AG
Julia Hofmann, Dr. Robert Mayer
Tel.: +49 - 89 - 20 00 33 - 33 01,
email: investor@medigene.com